Swiss Life Asset Management Ltd Purchases Shares of 2,692 Jazz Pharmaceuticals PLC $JAZZ

Swiss Life Asset Management Ltd acquired a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,692 shares of the specialty pharmaceutical company’s stock, valued at approximately $355,000.

Several other large investors have also modified their holdings of JAZZ. Royal Bank of Canada grew its holdings in Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after purchasing an additional 33,210 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Jazz Pharmaceuticals by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after purchasing an additional 7,954 shares during the last quarter. Focus Partners Wealth grew its stake in shares of Jazz Pharmaceuticals by 3.4% during the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Wells Fargo & Company increased their target price on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Needham & Company LLC upped their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Finally, TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $215.38.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 55,600 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the transaction, the executive vice president owned 56,862 shares in the company, valued at $10,892,484.72. This represents a 49.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the completion of the sale, the director directly owned 7,024 shares of the company’s stock, valued at $1,348,608. This trade represents a 32.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 68,015 shares of company stock worth $13,037,486. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $189.08 on Thursday. The firm has a fifty day moving average of $175.00 and a 200-day moving average of $159.26. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $11.64 billion, a P/E ratio of -31.67, a PEG ratio of 0.33 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business posted $6.51 EPS. The business’s quarterly revenue was up 8.1% on a year-over-year basis. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.